{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:42:43Z","timestamp":1776296563027,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pcl.2018.02.003","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T06:50:00Z","timestamp":1527144600000},"page":"509-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1016","volume":"65","author":[{"given":"Bradley P.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-180X","authenticated-orcid":false,"given":"Ralph A.","family":"Gruppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2018.02.003_bib1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2018.02.003_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tmrv.2014.08.004","article-title":"A\u00a0mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome","volume":"28","author":"Tsai","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.pcl.2018.02.003_bib3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pcl.2018.02.003_bib4","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2018.02.003_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in\u00a0acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2018.02.003_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2006-939767","article-title":"Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome","volume":"32","author":"Zimmerhackl","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pcl.2018.02.003_bib7","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"key":"10.1016\/j.pcl.2018.02.003_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcl.2018.02.003_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","article-title":"The global aHUS registry: methodology and initial patient characteristics","volume":"16","author":"Licht","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-14-3","article-title":"Thromboctopenia is not mandatory to diagnose haemolytic and uremic syndrome","volume":"14","author":"Sallee","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib12","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Lecleerc","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00467-013-2709-z","article-title":"Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement","volume":"29","author":"Hu","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.ajkd.2013.09.020","article-title":"Skin involvement in atypical hemolytic uremic syndrome","volume":"63","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcl.2018.02.003_bib15","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1542\/peds.2012-0903","article-title":"Peripheral gangrene in children with atypical hemolytic uremic syndrome","volume":"131","author":"Malina","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.pcl.2018.02.003_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.pcl.2018.02.003_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib18","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura","volume":"100","author":"Bianchi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib20","first-page":"127","article-title":"Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura","volume":"6","author":"Franchini","year":"2008","journal-title":"Blood Transfus"},{"key":"10.1016\/j.pcl.2018.02.003_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pcl.2018.02.003_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","article-title":"Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity","volume":"46","author":"Kato","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.pcl.2018.02.003_bib23","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/jth.12319","article-title":"An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura","volume":"11","author":"Muia","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"Suppl 11","key":"10.1016\/j.pcl.2018.02.003_bib24","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"RR12","key":"10.1016\/j.pcl.2018.02.003_bib25","first-page":"1","article-title":"Recommendations for diagnosis of Shiga toxin-producing Escherichia coli infections by clinical laboratories","volume":"58","author":"Gould","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.pcl.2018.02.003_bib26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib27","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib28","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.imbio.2016.10.014","article-title":"Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies","volume":"222","author":"Farkas","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/j.pcl.2018.02.003_bib30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib31","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavrilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib32","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00467-010-1446-9","article-title":"DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome","volume":"25","author":"Zipfel","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib33","series-title":"GeneReviews","article-title":"Genetic atypical hemolytic-uremic syndrome","author":"Noris","year":"1993"},{"key":"10.1016\/j.pcl.2018.02.003_bib34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2018.02.003_bib36","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2018.02.003_bib37","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcl.2018.02.003_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcl.2018.02.003_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pcl.2018.02.003_bib41","first-page":"347","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib42","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pcl.2018.02.003_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pcl.2018.02.003_bib44","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcl.2018.02.003_bib45","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2018.02.003_bib46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli 0104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pcl.2018.02.003_bib47","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","article-title":"Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement","volume":"94","author":"Pape","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.pcl.2018.02.003_bib48","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.pcl.2018.02.003_bib49","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. Coli O104:h4 induced haemolytic-uraemic syndrome: an analysis of the German STE C-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pcl.2018.02.003_bib50","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cix218","article-title":"Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli 0104:H4","volume":"64","author":"Loos","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pcl.2018.02.003_bib51","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pcl.2018.02.003_bib52","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.12387","article-title":"Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up","volume":"162","author":"Tsai","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pcl.2018.02.003_bib53","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.ajkd.2015.06.032","article-title":"Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab","volume":"66","author":"Pecoraro","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcl.2018.02.003_bib54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","article-title":"Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis","volume":"199","author":"Bettoni","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pcl.2018.02.003_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.pcl.2018.02.003_bib56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamics monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.pcl.2018.02.003_bib57","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcl.2018.02.003_bib59","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.pcl.2018.02.003_bib60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2018.02.003_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395518300257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395518300257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T15:17:44Z","timestamp":1617635864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395518300257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0031395518300257"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2018.02.003","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical Hemolytic Uremic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2018.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}